Tenax Therapeutics (TENX) Competitors $5.98 -0.02 (-0.25%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. BMEA, ANEB, MGNX, SAVA, TCRX, ANRO, SPRO, HLVX, CNTB, and SKYEShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), MacroGenics (MGNX), Cassava Sciences (SAVA), TScan Therapeutics (TCRX), Alto Neuroscience (ANRO), Spero Therapeutics (SPRO), HilleVax (HLVX), Connect Biopharma (CNTB), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Biomea Fusion Anebulo Pharmaceuticals MacroGenics Cassava Sciences TScan Therapeutics Alto Neuroscience Spero Therapeutics HilleVax Connect Biopharma Skye Bioscience Biomea Fusion (NASDAQ:BMEA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Which has higher earnings and valuation, BMEA or TENX? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$138.43M-$3.03-0.67Tenax TherapeuticsN/AN/A-$17.60M-$0.92-6.49 Does the media refer more to BMEA or TENX? In the previous week, Biomea Fusion had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Biomea Fusion and 2 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.93 beat Biomea Fusion's score of 0.65 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer BMEA or TENX? Biomea Fusion currently has a consensus price target of $14.80, indicating a potential upside of 630.86%. Tenax Therapeutics has a consensus price target of $17.00, indicating a potential upside of 184.52%. Given Biomea Fusion's higher possible upside, equities analysts clearly believe Biomea Fusion is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is BMEA or TENX more profitable? Tenax Therapeutics' return on equity of -31.34% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -243.95% -140.74% Tenax Therapeutics N/A -31.34%-30.39% Which has more risk and volatility, BMEA or TENX? Biomea Fusion has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Do institutionals & insiders believe in BMEA or TENX? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 18.4% of Biomea Fusion shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryBiomea Fusion and Tenax Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.25M$3.09B$5.68B$9.65BDividend YieldN/A2.28%6.66%4.53%P/E Ratio-6.4920.9782.7326.36Price / SalesN/A402.62536.75111.24Price / CashN/A43.5325.6628.92Price / Book0.229.9511.306.04Net Income-$17.60M-$54.01M$3.27B$265.75M7 Day Performance1.27%-0.33%0.01%-0.35%1 Month Performance-3.94%8.93%8.17%5.54%1 Year Performance49.75%7.47%54.17%17.46% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.7168 of 5 stars$5.98-0.3%$17.00+184.5%+50.1%$27.25MN/A-6.499BMEABiomea Fusion3.5658 of 5 stars$1.81-1.1%$16.80+828.2%-73.4%$108.90MN/A-0.6050ANEBAnebulo Pharmaceuticals2.4364 of 5 stars$2.70+3.8%$5.50+103.7%+30.2%$106.82MN/A-10.384News CoverageGap DownMGNXMacroGenics4.3945 of 5 stars$1.64-3.0%$3.60+119.5%-49.6%$106.82M$149.96M-2.88430SAVACassava Sciences2.5133 of 5 stars$2.16-1.8%$2.00-7.4%-92.1%$106.28MN/A-0.8530Positive NewsTCRXTScan Therapeutics3.234 of 5 stars$1.90+1.6%$7.80+310.5%-68.0%$106.12M$2.82M-1.74100Positive NewsANROAlto Neuroscience2.848 of 5 stars$3.93+0.8%$8.50+116.3%-71.1%$105.60MN/A-1.64N/ASPROSpero Therapeutics4.2887 of 5 stars$1.85-1.1%$5.00+170.3%+51.1%$105.24M$47.98M-1.89150Positive NewsShort Interest ↓HLVXHilleVax1.9164 of 5 stars$2.12+2.9%$2.00-5.7%+11.8%$103.29MN/A-1.4820Positive NewsShort Interest ↓CNTBConnect Biopharma2.7381 of 5 stars$1.87+2.2%$7.00+274.3%+28.8%$101.97M$1.97M0.00110Positive NewsUpcoming EarningsShort Interest ↑Gap UpSKYESkye Bioscience2.0828 of 5 stars$3.54+7.6%$15.50+337.9%-43.5%$101.95MN/A-3.3411News Coverage Related Companies and Tools Related Companies Biomea Fusion Alternatives Anebulo Pharmaceuticals Alternatives MacroGenics Alternatives Cassava Sciences Alternatives TScan Therapeutics Alternatives Alto Neuroscience Alternatives Spero Therapeutics Alternatives HilleVax Alternatives Connect Biopharma Alternatives Skye Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENX Stock Alerts